Real-World REVIEW Study Finds Significant Improvements in Chronic Migraine Symptoms and Reported Brain Fog with Vyepti Treatment

A real-world evidence study in participants with chronic migraine who used a prior preventive therapy revealed that the use of Vyepti (eptinezumab-jjmr; Lundbeck, Copenhagen, Denmark) was associated with a 2-fold increase in average “good days” per month. Vyepti use was also associated with a significant decrease in acute medication days per month and a reduction in reported brain fog/cognitive impairment. The results of this study were presented at the 2023 Scottsdale Headache Symposium.

The REVIEW study was an observational real-world study conducted at 4 sites in the United States, which included 94 adult participants with a diagnosis of chronic migraine who were treated with at least 2 consecutive Vyepti infusion cycles. These participants had tried prior therapies, which failed, with 89% having previous exposure to a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb). Analysis was conducted via a patient survey and a semi-structured interview with a health care provider.

• The average number of “good days" per month prior to Vyepti treatment was 8, which increased to 18 after beginning treatment with Vyepti.
• 81% and 66% of participants respectively reported using prescription and over-the-counter (OTC) medication for acute migraine treatment at least 10 days per month, which decreased to 26% and 23% of participants following Vyepti treatment.
• Prior to the start of Vyepti treatment, 80% of participants reported cognitive symptoms associated with their chronic migraine constituting “brain fog.” After the start of treatment with Vyepti, 86% of participants reported their “brain fog” symptoms as improving to some degree, with 5% reporting complete improvement, and 32% reporting that their symptoms were very much improved. 

“When you talk to migraine specialists, they say that a majority of their patients report what we would classify as ‘cognitive impairment’,” said Dr. Marija S. Geertsen, Vice President of US Medical Affairs at Lundbeck. “So that's why the piece of data we are presenting from the REVIEW study on improvement in cognitive impairment is especially important.”